reviewClinical & Experimental AllergySep 10, 2019BRONZE OA

Mechanisms of Dupilumab

Boston Children's Hospital · Harvard University

PubMed
Indexed incrossrefpubmed

Abstract

The Th2 cytokines interleukin 4 (IL-4) and IL-13 and the heterodimeric IL-4 receptor (IL-4R) complexes that they interact with play a key role in the pathogenesis of allergic disorders. Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL-4 receptor alpha chain (IL-4Rα), common to both IL-4R complexes: type 1 (IL-4Rα/γc; IL-4 specific) and type 2 (IL-4Rα/IL-13Rα1; IL-4 and IL-13 specific). In this review, we detail the current state of knowledge of the different signalling pathways coupled to the IL-4R complexes and examine the possible mechanisms of Dupilumab action and survey its clinical efficacy in different allergic disorders. The development of Dupilumab and the widening spectrum of its…

Citation impact

472
total citations
FWCI
28.86
Percentile
100%
References
93
Citations per year

Authors

2

Topics & keywords

Keywords
  • Dupilumab
  • Medicine
  • Immunology
  • Dermatology
  • Atopic dermatitis
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding